Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

<p>QTORIN™ rapamycin has potential to be first approved therapy and standard of care in the U.S. for Microcystic Lymphatic Malformations Microcystic Lymphatic Malformations is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S. WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) &#8212; Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/palvella-therapeutics-announces-u-s-fda-breakthrough-therapy-designation-granted-to-qtorin-3-9-rapamycin-anhydrous-gel-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic/">Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>